Product Datasheet

Bismuth subcitrate potassium


Catalog No. **BP-08916** · CAS **880149-29-1** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-11-16**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Antibiotic; Bacterial	**Infection**

Molecular formula	$C_{12}H_8BiK_5O_{14}$
Molecular weight	**780.6520**

STRUCTURE



DESCRIPTION

Bismuth subcitrate potassium is a compound bismuth salt with oral activity. Bismuth subcitrate potassium has antibacterial activity and can inhibit the growth of Campylobacter pyloridis with a MIC50 of 8 μg/mL. Bismuth subcitrate potassium can be used in the study of gastrointestinal diseases infected by Campylobacter pyloridis .

BIOLOGICAL ACTIVITY

In Vitro

Bismuth subcitrate potassium inhibits Helicobacter pylori, and can be used for a combination formulation (Pylera-Axcan) for ameliorating H. pylori infection and duodenal ulcer disease[3].

REFERENCES

[1]. Van Caekenberghe DL, et al. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother. 1987 Sep;31(9):1429-30. (https://www.ncbi.nlm.nih.gov/pubmed/3674850)

[2]. Malfertheiner P, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13. (https://www.ncbi.nlm.nih.gov/pubmed/21345487)

[3]. Hussar DA. New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine. J Am Pharm Assoc (2003). 2007 Jul-Aug;47(4):539-43. (https://pubmed.ncbi.nlm.nih.gov/17616504/)